Drug Trial Radar · NCT07712536
Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 4, 2025
Primary completion
Dec 19, 2025
Study completion Dec 19, 2025
Sponsor
- Lead sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the population pharmacokinetic characteristics of QY201 Tablets in adolescent participants with moderate to severe atopic dermatitis (AD).
Conditions
- Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
Interventions
QY201 Tablets(10mg)Drug
10 mg twice daily for 28 consecutive days
QY201 Tablets(20mg)Drug
20 mg twice daily for 28 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma concentrations of QY201 at multiple time points; population pharmacokinetic (PopPK) profiles of QY201Time frame: Day29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.